Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Janssen Seeks Approval of Psoriasis Drug

October 10, 2014 10:34 am | News | Comments

Janssen-Cilag International NV (Janssen) announced that a Type 2 Variation has been filed with the European Medicines Agency seeking approval of Stelara (ustekinumab) for the treatment of moderate to severe plaque psoriasis in pediatric patients ages 12 to 17 years old who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies. Read more...

TOPICS:

Amgen's ALL Drug Receives FDA Priority Review

October 10, 2014 10:23 am | News | Comments

Amgen announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for the investigational bispecific T cell engager (BiTE) antibody construct, blinatumomab. Read more...

TOPICS:

The Dwindling Stock of Antibiotics, and What to Do About It

October 10, 2014 10:13 am | by Diana Lutz | News | Comments

The Centers for Disease Control and Prevention has said that at least 2 million Americans are sickened by antibiotic resistant infections each year and survive. Read more...                        

TOPICS:
Advertisement

Giant Step Toward New Diabetes Treatment

October 10, 2014 9:55 am | News | Comments

Harvard stem cell researchers announced that they have made a giant leap forward in the quest to find a truly effective treatment for type 1 diabetes, a condition that affects an estimated 3 million Americans at a cost of about $15 billion annually Read more...

TOPICS:

Canadian Ebola Vaccine to Be Shipped to Geneva Next Week, WHO Said

October 10, 2014 9:35 am | by Helen Branswell, The Canadian Press | News | Comments

Experimental Ebola vaccine that Canada has donated to the World Health Organization will be shipped to Geneva next week, the global health agency said. Read more...                                   

TOPICS:

Shaping the Future of Immunotherapy: Four Trends to Watch

October 10, 2014 8:30 am | by Merrilyn Datta, Ph.D., Chief Commercial Officer, Definiens | Articles | Comments

Just four years after the drug sipuleucel-T was approved for clinical adoption, the field of immunotherapy is on the cusp of a number of exciting advancements. Read more...                           

TOPICS:

NIH Invests Nearly $32M to Increase Utility of Biomedical Research Data

October 9, 2014 3:26 pm | News | Comments

Wide-ranging National Institutes of Health grants announced will develop new strategies to analyze and leverage the explosion of increasingly complex biomedical data sets, often referred to as Big Data. Read more...

TOPICS:

Cancer Drug Destroys Tumors in Pre-Clinical Trials

October 9, 2014 3:18 pm | News | Comments

Scientists at QIMR Berghofer Medical Research Institute have used an experimental drug produced from the seeds of a rainforest plant to cure solid cancer tumors in preclinical trials. Read more...                     

TOPICS:
Advertisement

Endo Intl to Buy Auxilium in Deal Worth $2.6B

October 9, 2014 3:09 pm | News | Comments

Ireland's Endo International is planning to buy Auxilium Pharmaceuticals in a sweetened cash-and-stock deal valued at $2.6 billion a few weeks after Auxilium rejected a lower bid. The Auxilium board embraced the latest offer but its shareholders get to vote on it. Read more...

TOPICS:

Purdue Pharma Launches Smaller Dosage of Chronic Pain Patch

October 9, 2014 3:03 pm | News | Comments

Purdue Pharma L.P. announced the U.S. commercial launch of the new 7.5 mcg/hour dosage strength of Butrans (buprenorphine) Transdermal System CIII. Five strengths of Butrans are now available: 5 mcg/hour, 7.5 mcg/hour, 10 mcg/hour, 15 mcg/hour and 20 mcg/hour. Read more...

TOPICS:

New Technique Yields Fast Results in Drug, Biomedical Testing

October 9, 2014 2:50 pm | News | Comments

A new technique makes it possible to quickly detect the presence of drugs or to monitor certain medical conditions using only a single drop of blood or urine, representing a potential tool for clinicians and law enforcement. Read more...       

TOPICS:

Patient's Response, Resistance to Cancer Drug Traced to Mutations

October 9, 2014 2:25 pm | News | Comments

The DNA of a woman whose lethal thyroid cancer unexpectedly “melted away” for 18 months has revealed new mechanisms of cancer response and resistance to the drug everolimus. Read more...                      

TOPICS:

DelMar Pharmaceuticals' Cancer Drug Shows Promise

October 9, 2014 10:49 am | News | Comments

DelMar Pharmaceuticals Inc., a clinical-stage oncology company, announced the presentation of promising new data supporting the activity of its lead drug compound, VAL-083, in the treatment of non-small cell lung cancer (NSCLC). Read more...

TOPICS:

Amgen Says Version of Humira Meets Study Goal

October 9, 2014 10:42 am | by The Associated Press | News | Comments

Amgen said that its version of Humira, the best-selling drug in the world, worked as well as the original medication in a late-stage clinical trial. Read more...                             

TOPICS:

Fixing Faulty Molecular ‘Transport Hub’ Could Slow Brain Degeneration

October 9, 2014 10:36 am | News | Comments

University of Queensland researchers have gained new insights into how the body sorts and transports protein ‘cargo’ within our cells, in a finding that could eventually lead to treatments for neurodegenerative diseases such as Alzheimer’s and Parkinson’s. Read more...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading